Title :

Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France.

Author(s) :

Podevin, Pauline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cottencin, Anne-Caroline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Becquart, Coralie [Auteur]
Centre hospitalier [Valenciennes, Nord]
Azib, Selma [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Duparc, Adeline [Auteur]
Centre hospitalier [Valenciennes, Nord]
Darras, Sophie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Centre Hospitalier Boulogne-sur-mer
Florin, Valérie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Faiz, Sarah [Auteur]
Centre Hospitalier [Douai, Nord]
Duvert Lehembre, Sophie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Staumont, delphine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Dezoteux, Frédéric [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]

Journal title :

European Journal of Dermatology

Abbreviated title :

Eur J Dermatol

Volume number :

33

Pages :

34-40

Publication date :

2023-05-11

ISSN :

1952-4013

English keyword(s) :

apremilast
cancer
malignancy
psoriasis

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Psoriasis is a common inflammatory dermatosis with a strong impact on quality of life and associated comorbidities [1–6]. Treatment must be adapted to the severity of the disease and the patients’ comorbidities. Local ...
Show more >Psoriasis is a common inflammatory dermatosis with a strong impact on quality of life and associated comorbidities [1–6]. Treatment must be adapted to the severity of the disease and the patients’ comorbidities. Local treatments are the first line, as well as phototherapy. Then, in case of failure or more severe forms, conventional systemic treatments and biological therapies can be proposed. Apremilast (APR) is an oral phosphodiesterase inhibitor 4 [7], indicated for the treatment of [...]Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-11T22:48:26Z
2024-03-22T14:37:00Z